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Background: Infectious etiology in lymphoproliferative diseases has always been suspected. The pathogenic roles
of human herpesvirus-6 (HHV-6) in acute leukemia have been of great interest. Discordant results to establish a link
between HHV-6 activation and the genesis of acute leukemia have been observed. The objective of this study was
to evaluate a possible association between HHV-6 infection and acute leukemia in children and adults, with a
longitudinal follow-up at diagnosis, aplasia, remission and relapse.
Methods: HHV-6 load was quantified by a quantitative real-time PCR in the blood and bone marrow samples from
37 children and 36 adults with acute leukemia: 33 B acute lymphoblastic leukemia (B-ALL), 6 T acute lymphoblastic
leukemia (T-ALL), 34 acute myeloid leukemia (AML).
Results: HHV-6 was detected in 15%, 8%, 30% and 28% of the blood samples at diagnosis, aplasia, remission and
relapse, respectively. The median viral loads were 138, 244, 112 and 78 copies/million cells at diagnosis, aplasia,
remission and relapse, respectively. In the bone marrow samples, HHV-6 was detected in 5%, 20% and 23% of the
samples at diagnosis, remission and relapse, respectively. The median viral loads were 34, 109 and 32 copies/million
cells at diagnosis, remission and relapse, respectively. According to the type of leukemia at diagnosis, HHV-6 was
detected in 19% of the blood samples and in 7% of the bone marrow samples (with median viral loads at 206 and
79 copies/million cells, respectively) from patients with B-ALL. For patients with AML, HHV-6 was present in 8% of
the blood samples and in 4% of the bone marrow samples (with median viral loads at 68 and 12 copies/million
cells, respectively). HHV-6 was more prevalent in the blood samples from children than from adults (25% and 9%,
respectively) and for the bone marrow (11% and 0%, respectively). All typable HHV-6 were HHV-6B species. No link
was shown between neither the clinical symptoms nor the abnormal karyotype and HHV-6 activation. A case of
HHV-6 chromosomal integration was shown in one patient with AML.
Conclusion: This study confirms the absence of role of HHV-6 in the genesis of acute leukemia but the virus was
reactivated after chemotherapy treatment.
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Human herpesvirus-6 (HHV-6) belongs to the Roseolo-
virus genus of the Betaherpesvirinae subfamily of
the Herpesviridae family. HHV-6 was first isolated from
B-lymphocytes of patients with lymphoproliferative dis-
orders [1]. HHV-6 is separated into two major sub-
groups, novo designed species, HHV-6A and-6B on the
basis of distinct genetic, immunological and biological
characteristics [2].
HHV-6 genome is a linear, double-stranded DNA mol-
ecule, 160 to 162 kpb in size, flanked by terminal direct
repeats (DRL and DRR) of 8 to 9 kpb. The unique long
(UL) region is interrupted by three intermediate repeats,
R1, R2 and R3, in the immediate-early A region. The
genes in UL are termed U1 to U100 and open reading
frames (ORFs) within the direct repeats are designated
as DR1 to DR7 [3].
The cellular receptor of HHV-6 is CD46, expressed on
the surface of normal and malignant cells as well as on
leukemic cells [4]. HHV-6 oncogenic potential was
demonstrated in vitro in NIH3T3 cells [5], and ORF-1,
also referred to as DR7, was identified as an oncogene.
The binding of DR7 to the tumor suppressor protein
p53 and the inhibition of p53 activated transcription
were evidenced. Along with the detection of DR7 in
malignant tissues, these activities may indicate a role of
DR7 in human cancer [6]. Recently, the presence of
HHV-6 and the expression of the viral DR7B oncopro-
tein in Reed-Sternberg cells from Hodgkin’s lymphoma
patients have been reported [7].
An interesting feature is the integration of HHV-6
(CI-HHV-6) DNA into the cellular genome which is
found in about 1% of the general population. This
phenomenon was described in patient with acute
lymphoblastic leukemia and is transmitted from parents
to children through generations [8]. Interestingly, a care-
ful review of the literature shows some pathologies like
hematological neoplasia, appear overrepresented [9].
The insertion of the whole genome of HHV-6 (162 kpb)
within the telomeric regions could have consequences in
terms of cell physiology.
Acute leukemia is a multifactorial disease where an
infectious etiology is suspected. The role of HHV-6 in
the development of hematological disease is of con-
tinuous interest. Discordant results to establish a link
between HHV-6 infection and the genesis of acute
leukemia were observed in a prospective study. Human
herpesvirus-6 was found in leukemic cells of patients
with T-ALL [10]. The median viral loads were at 1,512
copies/million cells for patients with lymphoproliferative
disorders [11] and at 1,374 copies/million cells for
patients with B-cell malignancies [12]. On the contrary,
HHV-6 was similarly detected in patients with acute
lymphoblastic leukemia and controls [13], and the viruswas more present in children with acute lymphoblastic
leukemia at complete remission than at diagnosis [14].
The present work is aimed at carrying out a follow-up
study and evaluating a possible association of HHV-6 in
children and adults with acute leukemia at diagnosis,
aplasia, remission and relapse.
Results
Analysis of HHV-6 detection and quantitation
Overall, HHV-6 was more prevalent in blood (70% of
positive samples) than in bone marrow (30% of positive
samples) (p = 0.03) with a higher median viral load (136
and 12 copies/million cells, respectively, p = 0.02).
The detection of HHV-6 showed a significant dif-
ference among the different clinical stages (p = 0.02,
Table 1).
In the blood samples, HHV-6 was detected in 15%,
8%, 30% and 28% at diagnosis, aplasia, remission and
relapse, respectively. HHV-6 detection was significantly
higher at remission than at diagnosis (p = 0.04) or dur-
ing aplasia (p = 0.005), and higher at relapse than at
diagnosis (p = 0.06) or during aplasia (p = 0.02).
In the bone marrow samples, HHV-6 was detected in
a similar way as in the blood samples. It was not possible
to collect bone marrow samples from patients at the
time of aplasia. HHV-6 detection rate was different dur-
ing the remaining three stages (p = 0.04). As observed
for the blood samples, HHV-6 detection rate increased
in samples at remission (p = 0.01) and at relapse
(p = 0.03) compared to diagnosis.
Statistically, no significant viral load differences were
observed between samples at different disease stages
(Table 1).
When considering the age groups some significant
differences were evidenced. Thus, the overall prevalence
of HHV-6 detection in the blood samples from children
(25%) was higher than that observed in adults (8%)
(p = 0.005), with median viral loads of 194 and 68 copies/
million cells, respectively. In the bone marrow samples,
HHV-6 was more prevalent in children (17%) than in
adults (3%) (p = 0.001), with median viral loads at 12
and 68 copies/million cells, respectively. The present
results also differed from children to adults according to
the stage of disease. Thus, for the blood samples from
children, HHV-6 was detected in 25%, 13%, 35% and
24% at diagnosis, aplasia, remission and relapse, respect-
ively (with viral loads at 274, 136, 118 and 125 copies/
million cells, respectively). As for the blood samples
from adults, HHV-6 detection rates were lower (9%, 3%,
18% and 19% at diagnosis, aplasia, remission and relapse,
respectively), with also lower viral loads (68, 68, 88 and
50 copies/ million cells, respectively). The same ten-
dency was observed in the bone marrow samples. For
children, HHV-6 was detected in 11%, 17% and 34% at
Table 1 Detection and quantitation of HHV-6 DNA in blood and bone marrow samples
Sample type Detection of HHV-6 (%) and quantitation (range) expressed as copies/million cells at
Diagnosis Aplasia Remission Relapse
Detection Quantitation Detection Quantitation Detection Quantitation Detection Quantitation
Blood 9 [15] a,b 138 (12 – 6 074074) 5 [8] c,d 244 (68 – 6 546567) 18 (30) a,c 112 (26 – 6 675980) 11 (28) b,d 78 (19 – 8 533719)
Bone marrow 3 [5] a,b 34 (12 – 123) Nc Nc 9 [16] a 109 (10 – 245) 8 [17] b 14 (4 – 78)
All types
of samples
12 [10] 206 (12 – 6 074074) 5 [8] 244 (68 – 6546 567) 27 (26) 114 (10 – 6 675 980) 19 (26) 14 (4 – 8 533 719)
Nc: Not collected; a p = 0.04 for blood; p = 0.01 for bone marrow; b p = 0.06 for blood; p = 0.03 for bone marrow; c p = 0.005; d p = 0.02.
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loads at 34, 125 and 30 copies/million cells, respectively).
For adults, HHV-6 detection rates were 0%, 9% and 8%
at diagnosis, remission and relapse, respectively, with
also lower viral loads at remission and relapse (94 and
14 copies/ million cells, respectively).
The results according to the type of leukemia at diag-
nosis are presented in Table 2. When considering the
frequency of HHV-6 detection according to the different
periods, HHV-6 was more present at remission and
relapse than at diagnosis and aplasia whatever the type
of leukemia considered. For patients with B-ALL, HHV-6
was detected in 12%, 27% and 23% of the blood samples
(median viral loads at 388, 97 and 92 copies/ million
cells, respectively) at aplasia, remission and relapse,
respectively. In the bone marrow samples, similar detec-
tion rates were observed: 24% and 28% (median viral
loads at 109 and 31 copies/million cells) at remission
and relapse, respectively.
For patients with AML, HHV-6 was equally detected
in 19% of the blood samples (median viral loads at 121
and 49 copies/million cells) at remission and relapse,
respectively. In the bone marrow samples, similar detec-
tion rates were observed: 15% and 28% (median viral
loads at 172 and 32 copies/million cells) at remission
and relapse, respectively. During aplasia, HHV-6 was
detected in 6% of the blood samples with a viral load at
156 copies/million cells.HHV-6 typing
In 57 samples, HHV-6 was typed as HHV-6B species.
However, it was not possible to type the detected virus
in six cases.Table 2 Detection and quantitation of HHV-6 according the t
Pathology Number of samples
(blood/bone marrow)
Detection of HHV-6 in
blood/bone marrow (%)
B-ALL 62 (31/30) 6/2 (19/7)
T-ALL 7 (5/2) 0
AML 64 (37/27) 3/1 (8/4)
All patients 133 (73/59) 9/3 (15/5)
B-ALL: B Acute Lymphoblastic Leukemia; T-ALL: T Acute Lymphoblastic Leukemia; AGenetic analysis
Among 60 patients with a karyotype that was determined
at diagnosis, 24 had a normal karyotype and 36 had
an abnormal one. HHV-6 was detected in four patients
with an abnormal karyotype (11%) and in five patients
with a normal karyotype (15%), without any statistical
correlation between HHV-6 detection and abnormal kar-
yotypes (p = 0.4). The representative abnormal karyotypes
of HHV-6 positive samples were t(8;5;17), t(8;16), t(9;22)
(4;9), t(8;21), t(15;17), t(8;21) –Y, t(2;6;14), t(12;15;17),
t(18;21), del(12p), del(11p), inv [18] + 8del (7q), del(9q) –
Y, inv[18] + 5 + 21, del[11] + 21, hyperdiploidy.
Correlation between HHV-6 detection and hematological
clinical disorders
The relationship analysis did not show any correlation
between hematological clinical disorders and HHV-6
detection rate (leucopenia, p = 0.8; lymphopenia, p = 0.7;
agranulocytosis, p = 0.6; severe lymphopenia, p = 0.6;
asthenia, p = 0.1; fever, p = 0.3).
Chromosomal integration
A high HHV-6 DNA load in blood at diagnosis
(6,074,074 copies/million cells), at aplasia (6,546,567
copies/million cells), at remission (6,675,980 copies/
million cells) and at relapse (8,553,719 copies/million
cells) was observed in one patient with AML. CI-HHV-6
was suspected and confirmed by measuring the viral
load in hair follicles (7,583,774 copies/million cells).
HHV-6 B species was identified.
This patient was a 50-year-old man with type 2 AML,
without a family history of leukemia. At diagnosis, the
patient had fever, asthenia, nausea, pancytopenia, anemiaype of acute leukemia at diagnosis
HHV-6 median load expressed
as copies/million cells (range)
in blood
HHV-6 median load expressed
as copies/million cells (range)
in bone marrow
206 (41 – 1 225) 79 (34 – 123)
0 0
68 (12 – 6 074 074) 12
206 (12 – 6 074 074) 34 (12–123)
ML: Acute Myeloid Leukemia.
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blood and 49% in the bone marrow and the karyotype
was normal 46, XY. Later, he received chemotherapy
and was in remission.
When the blood samples of the patient’s family mem-
bers (wife, son and daughter) were analyzed to search for
HHV-6 DNA chromosomal transmission, a high HHV-6
DNA load was detected for the son (3,456,376 copies/
million cells), and a low and negative viral load for the
daughter (18 copies/million cells) and the wife, respectively.
Discussion
The hypothesis of a potential role of HHV-6 infections
in acute leukemia in children and adults was verified
here by carrying out a follow-up study on Tunisian
patients using real-time PCR for virus quantitation in
peripheral blood and bone marrow samples at diagnosis,
aplasia, remission and relapse.
To our knowledge, this is the first follow-up study car-
ried out on Tunisian children and adults comparing, for
the same patients, HHV-6 detection rate and viral load
in peripheral blood and bone marrow samples at differ-
ent stages of acute leukemia.
In the present study, HHV-6 was detected in 17% of
the blood samples from children and adults with ALL at
diagnosis with a median viral load at 206 copies/million
cells. The results obtained by Hermouet et al. evidenced
a higher HHV-6 detection rate (36%) with also a higher
viral load at 1,374 copies/million cells [12]. These differ-
ences may be due to variability in patient cohorts, and
to different qPCR sensitivities.
In the bone marrow samples at diagnosis, the current
results are in accordance with previous findings obtained
by Seror et al. who detected HHV-6 in 17% of bone
marrow samples with a viral load at 23 copies/million
cells [14].
The current data showed the presence of HHV-6 in
5% of the bone marrow samples from adults and chil-
dren. As observed in the blood samples, these results
greatly differed from those obtained by Hermouet et al.
who detected HHV-6 in 41% of bone marrow samples
with a viral load at 206 copies/million cells [12].
At remission, HHV-6 was significantly more prevalent
in blood and bone marrow than at diagnosis, confirm-
ing the high frequency detection of HHV-6 in patients at
remission [14].
The present results evidenced the low detection of
HHV-6 in the bone marrow samples at diagnosis where
the median frequency of blastic cells was 81% (22% -
99%), but the presence of the virus at remission. This
proves the absence of HHV-6 in leukemic cells. The virus
detected was probably present in normal lymphocytes that
were found at low percentages at diagnosis of leukemia.
This can also explain the low viral load observed.Andre-Garnier et al. demonstrated that HHV-6 can in-
fect differentiated cells (lymphocytes) and very immature
cells (early bone marrow progenitors CD34+) and not
lymphoblasts [15]. The current study demonstrated the
presence of HHV-6 in bone marrow at remission at a
higher rate than at diagnosis. This result is in favor of the
presence of the virus in CD34+ cells or in circulating cells
carrying HHV-6 that go back into the bone marrow.
The higher prevalence of HHV-6 infection in case of
B-ALL than AML or T-ALL and in children compared
to adults may be due to primary HHV-6 infection
frequent at childhood and in the higher occurrence of
B-ALL that constitutes the most common cancer in child-
hood. It would be interesting to analyze surface markers
of B leukemic cells sorted and search for the presence of
HHV-6 genome.
HHV-6 was detected in samples from patients at
remission and relapse. Reactivation of latent HHV-6
during the course of anti-leukemia treatment may occur
and can be explained by the suppression of the immune
functions in aggressively-treated patients. However,
HHV-6 was detected only in 8% of patients at aplasia
when immunosuppression is at its highest. This can be
explained by the low number of CD3+ cells or reactiva-
tion of the virus in other sites of the organism.
The identification of only HHV-6 B species in this
study is in accordance with the results obtained by seror
al. [14], but differs from those obtained by Hermouet
et al. who identified 89% of HHV-6A species, and 11%
of HHV-6B [12]. This may be linked to the high number
of children included in our study, the frequent occur-
rence of HHV-6 infections during childhood and to
inter-laboratory technical discrepancies.
The clinical symptoms related to HHV-6 were studied
to establish a link with HHV-6 activation but no correl-
ation was observed in these patients.
This study reported a case of CI-HHV-6 in an adult
patient with AML. The 1.2% prevalence of CI-HHV-6
observed in our studied population is in agreement with
other studies in which CI-HHV-6 was present in 1.5% of
children with leukemia [16] and in 0.2 - 2.9% of different
human populations [17-20]. HHV-6 genome was trans-
mitted from father to son who does not have any signs
of a hematological disease.
Conclusions
In conclusion, this study supports a viral reactivation
after chemotherapy treatment rather than a causal role
of HHV-6 in the genesis of acute leukemia.
Methods
Ethical approval and consent
This study was approved by the ethics committee and
medical research of the Farhat Hached University hospital,
Table 3 Distribution of patients according to periods, age group and leukemia types
Sample Type Periods
Diagnosis (Ch/Adlt) Aplasia (Ch/Adlt) Remission (Ch/Adlt) Relapse (Ch/Adlt) All periods (Ch/Adlt)
Blood 73 (37/36) 60 (30/30) 60 ( 30/30) 39 (19/20) 232 (116/116)
Bone marrow 59 (29/30) Nc 45 (24/21 ) 35 (17/18) 139 (70/69)
All type of samples 132 (66/76) 60 (30/30) 105 (54/61) 74 (36/38) 371 (186/185)
Ch: Children; Adlt: Adult; Nc: Not collected.
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informed consent was obtained from each case patient
for publication of this report.
Patients and clinical samples
The present prospective study was carried out using
samples from patients with acute leukemia consulting
the Clinical Hematology Department (Farhat Hached
Hospital, Sousse, Tunisia). The data concerning each
patient were collected (Name, Sex, Age, and Address)
(data not shown). The follow-up study was performed
during the four principal stages of disease and treatment
(diagnosis, aplasia, remission and relapse).
Initially, a total of 73 patients were included in the
follow-up study. However, 13 out of them did not con-
tinue the experiment and were excluded from the statis-
tical analysis. The remaining 60 patients continued the
follow-up until the end of the experiment (Table 3).
They consisted of 30 B acute lymphoblastic leukemia
(B-ALL), 0 T acute lymphoblastic leukemia (T-ALL), and
30 acute myeloid leukemia (AML) at diagnosis. The blood
samples were taken from all patients whereas the bone
marrow sampling was not possible for all. Altogether, it
was possible to collect bone marrow samples only from
59 out of 73 patients at diagnosis (Table 3).
Sixty samples were collected at aplasia, 30 samples
from patients with B-ALL and 30 from patients with
AML. At remission, 60 samples were collected from
the same patients and at relapse, 23 samples wereTable 4 Oligonucleotides used
Primers and probes Orientation Sequ
HHV-6 detection
Taq1 + GACA






HHV-6 (A and B)
HHV-6A - TGGT
HHV-6B - TGGTcollected from patients with B-ALL and 16 from patients
with AML.
At diagnosis, the median percentage of blastic cells was
54% (range 25 – 96%) in blood and 81% (range 22 – 99%)
in bone marrow. Remission was established when leukemic
cells were less than 5% in bone marrow samples. The pa-
tient was considered at relapse when the percentage of
leukemic cells exceeded 5% in the bone marrow samples.
Thirty-nine patients out of 60 were found at the stage of
relapse (Table 3).
The median age of the patients was 21 years (range
1 – 66 years). The sex ratio (male/female) was 0.9.
DNA extraction
Total DNA (viral and cellular) from blood and bone
marrow samples was extracted from 200 μL of EDTA-
treated whole blood or bone marrow using QIAamp
DNA Blood Mini kit (Qiagen, Courtaboeuf, France)
according to the manufacturer’s instructions. DNA was
eluted in 200 μL of elution buffer and stored at −80°C
until use.
HHV-6 and cellular DNAs quantitation
The quantitation of the HHV-6 genome was carried out
using Taq 1, Taq 2 primers and H6S probe (Table 4),
as described previously [21]. In addition, the amplifica-
tion of the human albumin gene was performed using
Alb-forward, Alb-reverse primers and Alb-probe (Table 4),
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50 μL containing 25 μL of Taq Man Universal PCR
MasterMix (Applied Biosystems-Applera, Villebonsur-
Yvette, France), 200 nM of each primer, 100 nM of
specific probe, 10 μL of sterile water and 10 μL of DNA
extract. The amplification step was carried out through
a denaturation step at 50°C for 2 min and at 95°C for
10 min followed by 45 cycles (95°C for 15 sec, 60°C
for 1 min). Ten-fold serial dilutions of HHV-6 DNA from
HST cultured in MT4 cells or human DNA (Roche Diag-
nostics, Meylan, France) were used to establish standard
curves. The detection limit was 10 copies of viral gen-
omic equivalents per reaction.
The HHV-6 load was expressed as the number of viral
genomic equivalent copies per million of cells (copies/
million cells).
HHV-6 typing
The identification of species such as HHV-6 A or B was
performed for each positive sample. HHV-6 typing was
carried out using HHV-6A and HHV-6B specific primers
(Table 4), as described previously [23]. The detection
limit of this real-time PCR method was 10 copies of viral
genomic equivalents per reaction. In all experiments, the
reactions were carried out using PE-Applied Biosystem
Sequence Detector 7000 or 7500.
Statistical analysis
The Statview software (release 5.0, SAS institute) was
used to perform descriptive statistics, Mann–Whitney
test, Fisher’s test and ANOVA, as appropriate. p-value <
0.05 was considered as statistically significant.
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